Nonetheless, the results of the study contribute to an increasing body of evidence supporting the use of anti-HER2 targeted therapy for treating HER2-overexpressing breast cancer, and underscore the importance of considering patient-specific factors when determining optimal treatment strategies. Here, ERBB2 is linked to breast carcinoma.